Contacts
Christine Sizemore - Section Chief
- Cooperative Agreements for Product Development
- PK/PD
- Clinical drug resistance
- Molecular immunology
Robert Goldman
- Drug discovery
- Assay development for drug discovery
- Target identification
- Hit identification, lead development
- Pre-clinical drug development strategies
- Medicinal chemistry studies
- Molecular mechanism of mycobacterial drug resistance
Gail Jacobs
- All Fs and Ks
- Diagnostics development
- Diagnostics for implementation – all
- Mycobacterial physiology
- Bacterial Cell-to-cell signaling
- Bacterial virulence
- Bacterial secretion and role in host/pathogen interactions
Karen Lacourciere
- Genetic determinations of mycobacterial disease
- Mycobacterial gene regulation
- Genome wide associations
- Sequencing and Genomics
- Proteomics technology and applications
- Metabolomics
- Systems Biology
- Enzymology
- Microarray technology development
- Nanotechnology
- Imaging technology
- Target discovery technologies for drugs, vaccines and diagnostics
- Development of molecular and genetic tools for Mycobacterial research
Robin Mason
- Mycobacterial Epidemiology
- Domestic and international clinical research/studies/trials under grants and cooperative agreements
- Clinical trials under cooperative agreements for drugs
- Clinical studies in leprosy under grants
Dikoe Makhene, Medical Officer
- Medical oversight over all studies involving human subjects – grants and contracts
- Contact for all clinical trials, R34 concepts, U01 clinical trial concepts
- Representative of Section to OCRA and ORA on all medical and human subjects research
- Representative for all aspects of pediatric clinical research
- NIAID representative for clinical trials for TB
Tina Parker
- Immunology of Host/Pathogen interactions
- Animal models of infection and disease
- Animal models for testing of vaccines, diagnostics and drugs
- Vaccine and adjuvant development
- Clinical trial cooperative agreements for vaccines
RDB - Tuberculosis, Leprosy, and Other Mycobacterial Diseases Section 301-496-5305
back to top